|
Novartis Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved the company's new type 2 diabetes drug Starlix (nateglinide).
Starlix supposedly increases insulin release, thereby halting the mealtime glucose spikes often experienced by type 2 diabetes patients.
The new drug is to be used alone or in combination with other drugs such as Bristol-Myers Squibb's diabetes drugs Glucophage and Glucovance.
People with type 2 diabetes become insulin resistant (lose their sensitivity to insulin). The disease usually develops in adulthood and is often related to obesity. Currently, about 10 million people have been diagnosed with diabetes in the United States, most of whom have type 2.
|